San Diego—For the treatment of patients with moderate to severe Crohn’s disease (CD), inhibitors of two different pathways were effective in early trials reported at the 2016 Digestive Disease Week.
The results of an inhibitor of the interleukin (IL)-23 pathway were presented by an international team of researchers, while European investigators reported findings for the first selective Janus kinase 1 (JAK1) inhibitor to be studied in CD.
Clinical Remission Rate 39% With